Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 28.95M 33.13M 26.78M 24.99M 46.92M 3.13B 47.26M 318M 124M 1.54B 124M 122M 5.35B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 30.9M 35.37M 28.59M 26.68M 50.09M 3.34B 50.46M 340M 132M 1.64B 133M 130M 5.71B EV / Sales 2026 *
1.01x
EV / Sales 2027 * 0.97x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
6 months-5.90%
Current year-5.90%
Current year 0.48
Extreme 0.48
0.48
1 year 0.48
Extreme 0.48
0.55
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-.--% - - 33.2M
+0.95%+0.57%-37.69%-41.90% 547M
-4.08%-23.95%+187.15% - 431M
-0.28%-7.91%-36.10%+14.12% 132M
+3.66%+9.32%+65.05%+115.19% 129M
Average -1.13%-6.82%+44.60%+29.14% 309.73M
Weighted average by Cap. -0.79%-8.18%+51.45%-7.61%

Financials

2026 *2027 *
Net sales 30.52M 34.93M 28.24M 26.35M 49.47M 3.3B 49.84M 336M 131M 1.62B 131M 128M 5.64B 34.86M 39.9M 32.25M 30.1M 56.5M 3.77B 56.92M 383M 149M 1.85B 150M 147M 6.44B
Net income - -
Net Debt 1.96M 2.24M 1.81M 1.69M 3.17M 212M 3.19M 21.5M 8.37M 104M 8.4M 8.22M 361M 4.84M 5.54M 4.48M 4.18M 7.85M 524M 7.91M 53.22M 20.71M 257M 20.8M 20.35M 894M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!